Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.c

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

Publications

Escobar NS, Das A, Tabori U, Manson D, Grasemann H

Immune checkpoint inhibitor pneumonitis presenting with multifocal nodular opacities.

Thorax. 2026

Yamasaki M, Taniwaki M, Kawamoto K, Matsumoto N, Hashimoto K, Nabeshima S, Ohashi N, Hattori N

Durvalumab-induced Organizing Pneumonia with a Diffuse Micronodular Pattern in a Patient with Lung Cancer.

American journal of respiratory and critical care medicine. 2020;201(8):e52-e53

Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC

Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.

The American journal of surgical pathology. 2019;43(10):1331-1340

Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

Cancer treatment and research communications. 2018;15:17-20

Ortega Sanchez G, Jahn K, Savic S, Zippelius A, Läubli H

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.

Journal for immunotherapy of cancer. 2018;6(1):85

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(7):709-717

Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.

Chest. 2013;143(3):858-861